Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered ...

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer. News provided by.

Pfizer Media Contact: +1 (212) 733-1225 PfizerMediaRelations@Pfizer.com Pfizer Investor Contact: +1 (212) 733-4848 IR@Pfizer.com Arvinas Media Contact: ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients ...

--Arvinas, Inc. and Pfizer Inc. today announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients ...

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer. May 31, 2025 8:00 AM ET Pfizer Inc. ...